Chronic Heart Failure With Preserved Ejection Fraction: Effective Treatment Possible?
| Autor: | Y V Borisenko, S G Kanorskiy |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Ejection fraction business.industry 030204 cardiovascular system & hematology medicine.disease 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Heart failure Internal medicine Heart rate medicine Cardiology Effective treatment In patient 030212 general & internal medicine Cardiology and Cardiovascular Medicine Heart failure with preserved ejection fraction business Ivabradine medicine.drug |
| Zdroj: | Kardiologiia. 17:85-89 |
| ISSN: | 0022-9040 |
| DOI: | 10.18087/cardio.2018.6.10154 |
| Popis: | Chronic heart failure with preserved ejection fraction (HFpEF) accounts for about 50% of cases of heart failure, but pharmacotherapy that improves its outcomes has not been developed. The proven principle of improving outcomes in patients with chronic heart failure with a reduced of left ventricular ejection fraction is the decrease in heart rate. The article discusses situations in which treatment with s-blockers is not effective or negatively affects outcomes. The results of own research and the EDIFY project, in which ivabradine was used in patients with HFpEF, were compared. The importance of phenotyping patients with HFpEF is stated to increase the effectiveness of their therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|